Myconic Capital Corp. announced the appointment of a Chief Medical Officer, Chief Research Officer, as well as a President of Clinic Operations. Ketamine One's board of directors has appointed Dr. Mark Kimmins as the Company's Chief Medical Officer. Dr. Kimmins is a medical doctor and surgeon who is a Fellow of the American College of Surgeons, a Fellow of the Royal College of Surgeons of Canada, and a Fellow of the American Society of Colon and Rectal Surgeons. He has extensive experience in academic medicine, subspecialty community medicine, cannabis medicine and healthcare-related business, which are areas of expertise that will be applied to help lead as an officer of the Company. Najla Guthrie has been appointed by the Company's board of directors as Chief Research Officer. Ms. Guthrie joins Ketamine One as part of the previously announced acquisition of KGK Science Inc. from Auxly Cannabis Group Inc., where she has held the role of President & CEO since 1997. Over 23 years, Najla has grown the London-based business to become a leading North American contract research organization that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. Additionally, Keith White has been hired by the Company as President of Clinic Operations. Mr. White joins Ketamine One as part of the previously announced acquisition of 14 medical cannabis clinics, in the same role held with Aleafia Health to ensure the continuity and ongoing growth of the clinical assets. During his tenure, he led patient growth initiatives that resulted in an 84% annual increase in medical cannabis sales, while rapidly implementing scalable technological solutions to enable patient care to continue virtually during the COVID-19 pandemic.